Literature DB >> 24525151

Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization.

Brandi H Gorden1, Jong-Hyuk Kim1, Aaron L Sarver2, Aric M Frantz1, Matthew Breen3, Kerstin Lindblad-Toh4, Timothy D O'Brien5, Leslie C Sharkey6, Jaime F Modiano7, Erin B Dickerson8.   

Abstract

Canine hemangiosarcomas have been ascribed to an endothelial origin based on histologic appearance; however, recent findings suggest that these tumors may arise instead from hematopoietic progenitor cells. To clarify this ontogenetic dilemma, we used genome-wide expression profiling of primary hemangiosarcomas and identified three distinct tumor subtypes associated with angiogenesis (group 1), inflammation (group 2), and adipogenesis (group 3). Based on these findings, we hypothesized that a common progenitor may differentiate into the three tumor subtypes observed in our gene profiling experiment. To investigate this possibility, we cultured hemangiosarcoma cell lines under normal and sphere-forming culture conditions to enrich for tumor cell progenitors. Cells from sphere-forming cultures displayed a robust self-renewal capacity and exhibited genotypic, phenotypic, and functional properties consistent with each of the three molecular subtypes seen in primary tumors, including expression of endothelial progenitor cell (CD133 and CD34) and endothelial cell (CD105, CD146, and αvβ3 integrin) markers, expression of early hematopoietic (CD133, CD117, and CD34) and myeloid (CD115 and CD14) differentiation markers in parallel with increased phagocytic capacity, and acquisition of adipogenic potential. Collectively, these results suggest that canine hemangiosarcomas arise from multipotent progenitors that differentiate into distinct subtypes. Improved understanding of the mechanisms that determine the molecular and phenotypic differentiation of tumor cells in vivo could change paradigms regarding the origin and progression of endothelial sarcomas.
Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24525151      PMCID: PMC3969990          DOI: 10.1016/j.ajpath.2013.12.025

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.

Authors:  Gabriela Dontu; Wissam M Abdallah; Jessica M Foley; Kyle W Jackson; Michael F Clarke; Mari J Kawamura; Max S Wicha
Journal:  Genes Dev       Date:  2003-05-15       Impact factor: 11.361

2.  The dog as a cancer model.

Authors:  Chand Khanna; Kerstin Lindblad-Toh; David Vail; Cheryl London; Philip Bergman; Lisa Barber; Matthew Breen; Barbara Kitchell; Elizabeth McNeil; Jaime F Modiano; Steven Niemi; Kenine E Comstock; Elaine Ostrander; Susan Westmoreland; Stephen Withrow
Journal:  Nat Biotechnol       Date:  2006-09       Impact factor: 54.908

3.  Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals.

Authors:  Mervin C Yoder; Laura E Mead; Daniel Prater; Theresa R Krier; Karim N Mroueh; Fang Li; Rachel Krasich; Constance J Temm; Josef T Prchal; David A Ingram
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

4.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

5.  Pathogenesis of human hemangiosarcomas and hemangiomas.

Authors:  Liping Liu; Satoko Kakiuchi-Kiyota; Lora L Arnold; Sonny L Johansson; David Wert; Samuel M Cohen
Journal:  Hum Pathol       Date:  2013-10       Impact factor: 3.466

6.  Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach.

Authors:  Milcah C Scott; Aaron L Sarver; Katherine J Gavin; Venugopal Thayanithy; David M Getzy; Robert A Newman; Gary R Cutter; Kerstin Lindblad-Toh; William C Kisseberth; Lawrence E Hunter; Subbaya Subramanian; Matthew Breen; Jaime F Modiano
Journal:  Bone       Date:  2011-05-15       Impact factor: 4.398

Review 7.  Concise review: mesenchymal tumors: when stem cells go mad.

Authors:  Alexander B Mohseny; Pancras C W Hogendoorn
Journal:  Stem Cells       Date:  2011-03       Impact factor: 6.277

8.  NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.

Authors:  Xing Fan; Leila Khaki; Thant S Zhu; Mary E Soules; Caroline E Talsma; Naheed Gul; Cheryl Koh; Jiangyang Zhang; Yue-Ming Li; Jarek Maciaczyk; Guido Nikkhah; Francesco Dimeco; Sara Piccirillo; Angelo L Vescovi; Charles G Eberhart
Journal:  Stem Cells       Date:  2010-01       Impact factor: 6.277

9.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors.

Authors:  Shu Zhang; Curt Balch; Michael W Chan; Hung-Cheng Lai; Daniela Matei; Jeanne M Schilder; Pearlly S Yan; Tim H-M Huang; Kenneth P Nephew
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

Review 10.  Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance.

Authors:  Samuel M Cohen; Richard D Storer; Kay A Criswell; Nancy G Doerrer; Vicki L Dellarco; David G Pegg; Zbigniew W Wojcinski; David E Malarkey; Abigail C Jacobs; James E Klaunig; James A Swenberg; Jon C Cook
Journal:  Toxicol Sci       Date:  2009-06-12       Impact factor: 4.849

View more
  36 in total

1.  Magnetic resonance imaging and immunohistochemistry of primary vertebral hemangiosarcoma in a dog and implications for diagnosis and therapy.

Authors:  Claudia Pérez-Martínez; Marta Regueiro-Purriños; Beatriz Fernández-Martínez; José R Altónaga; José M Gonzalo-Orden; María J García-Iglesias
Journal:  Can Vet J       Date:  2016-12       Impact factor: 1.008

2.  Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.

Authors:  Mami Adachi; Yuki Hoshino; Yusuke Izumi; Hiroki Sakai; Satoshi Takagi
Journal:  Can J Vet Res       Date:  2016-07       Impact factor: 1.310

Review 3.  Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy?

Authors:  Hidetaka Shima; Akimitsu Yamada; Takashi Ishikawa; Itaru Endo
Journal:  Gland Surg       Date:  2017-02

4.  Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.

Authors:  Matthew Breen; Jaime F Modiano; Ingegerd Elvers; Kerstin Lindblad-Toh; Kate Megquier; Jason Turner-Maier; Ross Swofford; Jong-Hyuk Kim; Aaron L Sarver; Chao Wang; Sharadha Sakthikumar; Jeremy Johnson; Michele Koltookian; Mitzi Lewellen; Milcah C Scott; Ashley J Schulte; Luke Borst; Noriko Tonomura; Jessica Alfoldi; Corrie Painter; Rachael Thomas; Elinor K Karlsson
Journal:  Mol Cancer Res       Date:  2019-09-30       Impact factor: 5.852

5.  Identification of drug-resistant subpopulations in canine hemangiosarcoma.

Authors:  A Khammanivong; B H Gorden; A M Frantz; A J Graef; E B Dickerson
Journal:  Vet Comp Oncol       Date:  2014-08-11       Impact factor: 2.613

Review 6.  Comparative oncology: what dogs and other species can teach us about humans with cancer.

Authors:  Joshua D Schiffman; Matthew Breen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-19       Impact factor: 6.237

Review 7.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

8.  Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma.

Authors:  K S Im; A J Graef; M Breen; K Lindblad-Toh; J F Modiano; J-H Kim
Journal:  Vet Comp Oncol       Date:  2015-09-03       Impact factor: 2.613

9.  Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma.

Authors:  Antonella Borgatti; Ann Fieberg; Amber L Winter; Kathleen Stuebner; Elizabeth Taras; Deborah Todhunter; Alison Masyr; Aaron Rendhal; Daniel A Vallera; Joseph S Koopmeiners; Jaime F Modiano
Journal:  Vet Comp Oncol       Date:  2020-04-02       Impact factor: 2.613

10.  Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers.

Authors:  J-H Kim; A M Frantz; A L Sarver; B H Gorden Klukas; M Lewellen; T D O'Brien; E B Dickerson; J F Modiano
Journal:  Vet Comp Oncol       Date:  2017-11-20       Impact factor: 2.613

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.